fluvoxamine has been researched along with favipiravir* in 1 studies
1 trial(s) available for fluvoxamine and favipiravir
| Article | Year |
|---|---|
Efficacy of combination therapy of fluvoxamine and favipiravir vs favipiravir monotherapy to prevent severe COVID-19 among mild to moderate COVID-19 patients: Open-label randomized controlled trial (EFFaCo study).
Fluvoxamine (FVX) is an antidepressant proposed to its immunomodulatory effects in preventing deterioration in mild and moderate COVID-19.. An open-label, 1:1 randomized controlled trial was assigned either combination therapy 50 mg twice daily of FVX for 10 days and favipiravir (FPV) or FPV alone to assess the efficacy in preventing disease progression in mild to moderate COVID-19 on the 5. The combined fluvoxamine treatment did not add benefit in preventing deterioration in patients with mild to moderate COVID-19 without the immunomodulatory effect observed, although it demonstrated low hospitalization rates, oxygen supplemental, intensive care needed, and zero mortality.. Thai clinical trials registry (TCTR) no. 20210615002. Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Fluvoxamine; Humans; SARS-CoV-2; Treatment Outcome | 2023 |